Literature DB >> 1581233

Acquired type II von Willebrand's disease associated with adrenal cortical carcinoma.

T Facon1, C Caron, P Courtin, A Wurtz, M Deghaye, F Bauters, C Mazurier, J Goudemand.   

Abstract

A case of acquired von Willebrand's disease (AvWD) associated with an adrenal cortical carcinoma is reported. The circulating highest molecular weight multimers (HMWM) of von Willebrand factor (vWF) were decreased when assessed by SDS-agarose plasma electrophoresis, leading to the diagnosis of type II AvWD. No forms of inhibitor could be detected in the plasma of the patient. In contrast, indirect immunoperoxidase studies with a monoclonal antibody to vWF demonstrated an absorption of vWF into malignant cells. Infusion of a vWF-FVIII concentrate, containing significant amounts of HMWM of vWF, allowed surgical resection of the tumour. After the first infusion of the concentrate, the vWF-RCo recovery was found to be low (38%) compared to the vWF:Ag (75%) and FVIII:C (163%) recoveries. The resolution of all biological signs of vWD, including the abnormal multimeric pattern, in the post-operative period was prompt and permanent. Therefore, the absorption of the HMWM of vWF by carcinomatous cells appears to represent a likely pathophysiological mechanism responsible for the AvWD syndrome in this patient.

Entities:  

Mesh:

Year:  1992        PMID: 1581233     DOI: 10.1111/j.1365-2141.1992.tb04562.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  7 in total

1.  Acquired von Willebrand's disease associated with epithelial myoepithelial carcinoma of the parotid salivary gland.

Authors:  Geoffrey Spencer Chilvers; Graham Porter
Journal:  BMJ Case Rep       Date:  2014-08-05

Review 2.  Acquired von Willebrand syndrome: its pathophysiology, laboratory features and management.

Authors:  Hiroshi Mohri
Journal:  J Thromb Thrombolysis       Date:  2003-06       Impact factor: 2.300

Review 3.  High-dose intravenous gammaglobulin therapy for acquired von Willebrand disease.

Authors:  P J Van Genderen; D N Papatsonis; J J Michiels; J J Wielenga; J Stibbe; F J Huikeshoven
Journal:  Postgrad Med J       Date:  1994-12       Impact factor: 2.401

4.  Acquired von Willebrand's disease.

Authors:  B J Hennessy; B White; M Byrne; O P Smith
Journal:  Ir J Med Sci       Date:  1998 Apr-Jun       Impact factor: 1.568

5.  Acquired von Willebrand Disease Associated with Mantle Cell Lymphoma.

Authors:  Dominique Maas; Britta Laros-van Gorkom; Sanne Gianotten; Marjan Cruijsen; Waander van Heerde; Marten Nijziel
Journal:  Case Rep Hematol       Date:  2018-01-30

Review 6.  Von Willebrand disease in the elderly: clinical perspectives.

Authors:  John Chapin
Journal:  Clin Interv Aging       Date:  2018-08-31       Impact factor: 4.458

Review 7.  The Intriguing Connections between von Willebrand Factor, ADAMTS13 and Cancer.

Authors:  Chanukya K Colonne; Emmanuel J Favaloro; Leonardo Pasalic
Journal:  Healthcare (Basel)       Date:  2022-03-16
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.